{"a":[{"_":"FDA approves AstraZeneca’s Etcamah, opening ctDNA-guided treatment paradigm in breast cancer","$":{"href":"/pharma/fda-approves-astrazeneca-etcamah-opening-ctdna-guided-treatment-shift-breast-cancer","hreflang":"en"}}]}
RegulatoryapprovedEtcamahPositive
AI Analysis
Summary
FDA granted accelerated approval to AstraZeneca's camizestrant (Etcamah) for breast cancer, establishing a new ctDNA-guided treatment paradigm. The approval marks a divergence from the FDA's own expert panel recommendations.
Outcome Details
FDA granted accelerated approval for camizestrant (Etcamah)
Importance:9/10
Sentiment:
0.85
FDA approvalaccelerated approvalbreast cancerctDNAmolecular-guided therapyregulatory divergence
Related Companies
Read the original article
Published by FiercePharma on September 8, 2026 9:57 AM